Skip to main content
Clinical Trials/CTRI/2020/06/025977
CTRI/2020/06/025977CompletedPhase 2

A Randomized and Comparative Study to assess Safety and Efficacy of Supplemental Treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with Corona Virus 2019 (Covid-19)

Ms Shukla Ashar Impex Pvt Ltd0 sites120 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
120

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Subject willing to sign informed consent.
  • Subject age group of 18 years and above of both gender.
  • All patients with COVID-19 PCR positive (within 7 days/high clinical suspicion admitted to Corona Virus study participating hospital will be eligible.
  • Patients who are having mild to moderate symptoms of Covid-19 disease and tested positive for Covid-19 test.

Exclusion Criteria

  • Patients younger than 18 years.
  • Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.
  • Patients allergic to type medications or any of the ingredient of the formulation.
  • Patients with a neurological history (seizures, epilepsy, etc.).
  • Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).
  • Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study.
  • Patients who would require artificial ventilation or oxygen supply.
  • Very severe patients of Covid 19.
  • Patients with severe hypertension, diabetes shall be excluded.

Investigators

Sponsor
Ms Shukla Ashar Impex Pvt Ltd

Similar Trials

Completed
Phase 2
To study the Effectiveness of herbal formulation - Aayudh Advance as a supplementary treatment for the Corona Virus 2019 (Covid-19) infected patients
CTRI/2020/05/025161Ms Shukla Ashar Impex Pvt Ltd74
Recruiting
Phase 2
A clinical Trial on Oligospermia to evaluate the Siddha interventio
CTRI/2022/09/046073Central Council for Research in Siddha Ministry of AYUSH
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson's with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-002233-37-ITImpax Laboratories, LLC510
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-002233-37-DEImpax Laboratories, LLC510
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-002233-37-GBImpax Laboratories, LLC510